41.62
-0.56 (-1.33%)
Previous Close | 42.18 |
Open | 43.00 |
Volume | 1,556,516 |
Avg. Volume (3M) | 1,331,496 |
Market Cap | 4,911,742,464 |
Price / Sales | 1.39 |
Price / Book | 60.31 |
52 Weeks Range | |
Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
Operating Margin (TTM) | -30,410.58% |
Diluted EPS (TTM) | -5.38 |
Quarterly Revenue Growth (YOY) | 22.50% |
Total Debt/Equity (MRQ) | 727.94% |
Current Ratio (MRQ) | 9.28 |
Operating Cash Flow (TTM) | -404.36 M |
Levered Free Cash Flow (TTM) | -242.42 M |
Return on Assets (TTM) | -30.13% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Cytokinetics, Incorporated | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | 4.0 |
Insider Activity | -1.5 |
Price Volatility | 4.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.5 |
Average | 0.90 |
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 0.54% |
% Held by Institutions | 120.05% |
52 Weeks Range | ||
Price Target Range | ||
High | 120.00 (HC Wainwright & Co., 188.32%) | Buy |
Median | 81.00 (94.62%) | |
Low | 67.00 (Morgan Stanley, 60.98%) | Buy |
Average | 86.00 (106.63%) | |
Total | 8 Buy | |
Avg. Price @ Call | 45.12 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Morgan Stanley | 13 Feb 2025 | 67.00 (60.98%) | Buy | 41.62 |
Citigroup | 07 Feb 2025 | 86.00 (106.63%) | Buy | 42.76 |
JMP Securities | 07 Feb 2025 | 78.00 (87.41%) | Buy | 42.76 |
14 Jan 2025 | 78.00 (87.41%) | Buy | 45.23 | |
Needham | 06 Feb 2025 | 72.00 (72.99%) | Buy | 46.17 |
02 Dec 2024 | 72.00 (72.99%) | Buy | 50.63 | |
HC Wainwright & Co. | 22 Jan 2025 | 120.00 (188.32%) | Buy | 46.82 |
21 Jan 2025 | 120.00 (188.32%) | Buy | 45.82 | |
Stifel | 22 Jan 2025 | 80.00 (92.22%) | Buy | 46.82 |
RBC Capital | 18 Dec 2024 | 82.00 (97.02%) | Buy | 46.36 |
Mizuho | 21 Nov 2024 | 103.00 (147.48%) | Buy | 47.67 |
Show more |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
MALIK FADY IBRAHAM | - | 49.20 | -2,000 | -98,400 |
Aggregate Net Quantity | -2,000 | |||
Aggregate Net Value ($) | -98,400 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 49.20 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
MALIK FADY IBRAHAM | Officer | 04 Feb 2025 | Sell (-) | 2,000 | 49.20 | 98,400 |
MALIK FADY IBRAHAM | Officer | 04 Feb 2025 | Option execute | 2,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |